{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:04:41Z","timestamp":1778828681978,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jfo.2016.12.004","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T05:00:23Z","timestamp":1489726823000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pan-European survey of the topical ocular use of cyclosporine A"],"prefix":"10.1016","volume":"40","author":[{"given":"A.","family":"Labb\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Amrane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-S.","family":"Garrigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.C.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Van Setten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Labetoulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2016.12.004_bib0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1590\/S0004-27492008000700017","article-title":"Rationale for anti-inflammatory therapy in dry eye syndrome","volume":"71","author":"de Paiva","year":"2008","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/09273941003721926","article-title":"Dry eye disease as an inflammatory disorder","volume":"18","author":"Calonge","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jfo.2016.12.004_bib0215","first-page":"S432","article-title":"Understanding dry eye disease: a managed care perspective","volume":"17","author":"Fiscella","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jfo.2016.12.004_bib0220","first-page":"S88","article-title":"Management of dry eye disease","volume":"14","author":"Lemp","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jfo.2016.12.004_bib0225","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/OPTH.S1409","article-title":"Treatment of chronic dry eye: focus on cyclosporine","volume":"2","author":"Kymionis","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0230","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A","volume":"42","author":"Brignole","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2016.12.004_bib0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14740338.7.1.79","article-title":"Uses and safety profile of ciclosporin in ophthalmology","volume":"7","author":"Kashani","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jfo.2016.12.004_bib0240","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/14656566.2014.914492","article-title":"An update on dry eye disease molecular treatment: advances in drug pipelines","volume":"15","author":"Colligris","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jfo.2016.12.004_bib0245","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4155\/cli.14.135","article-title":"Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence","volume":"5","author":"Ames","year":"2015","journal-title":"Clin Investig (Lond)"},{"key":"10.1016\/j.jfo.2016.12.004_bib0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jtos.2014.12.006","article-title":"Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis","volume":"13","author":"Wan","year":"2015","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2016.12.004_bib0255","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00055735-200408000-00004","article-title":"Dry eye diagnosis and management in 2004","volume":"15","author":"Perry","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1350-9462(02)00006-X","article-title":"Vernal keratoconjunctivitis: pathogenesis and treatment","volume":"21","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jfo.2016.12.004_bib0265","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11882-013-0345-0","article-title":"Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis","volume":"13","author":"Vichyanond","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jfo.2016.12.004_bib0270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/pai.12197","article-title":"Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes","volume":"25","author":"Vichyanond","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0275","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.iac.2010.06.004","article-title":"Atopic dermatitis and keratoconjunctivitis","volume":"30","author":"Bielory","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jfo.2016.12.004_bib0280","first-page":"CD009078","article-title":"Topical cyclosporine for atopic keratoconjunctivitis","volume":"9","author":"Gonzalez-Lopez","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfo.2016.12.004_bib0285","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jfo.2011.10.002","article-title":"[Current concepts in the treatment of herpetic keratitis]","volume":"35","author":"Labetoulle","year":"2012","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0290","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00041327-200412000-00015","article-title":"Persistent visual loss from neurotrophic corneal ulceration after dorsolateral medullary infarction (Wallenberg syndrome)","volume":"24","author":"Hipps","year":"2004","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0295","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jfo.2011.02.001","article-title":"[Rejection of corneal allografts]","volume":"34","author":"Guilbert","year":"2011","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0300","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/01.ico.0000138841.44926.f8","article-title":"Opinions on risk factors and management of corneal graft rejection in the United Kingdom","volume":"24","author":"Koay","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2016.12.004_bib0305","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ICO.0b013e31818c69ef","article-title":"Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye","volume":"31","author":"Byun","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2016.12.004_bib0310","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1136\/bjophthalmol-2013-304728","article-title":"Topical cyclosporine: are all indications justified?","volume":"98","author":"Aragona","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0315","unstructured":"European Medicines Agency. Ikervis authorisation. Available at http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002066\/human_med_001851.jsp&mid=WC0b01ac058001d124 [Accessed December 6, 2015]."},{"key":"10.1016\/j.jfo.2016.12.004_bib0320","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1177\/0018726708094863","article-title":"Survey response rate levels and trends in organizational research","volume":"61","author":"Baruch","year":"2008","journal-title":"Hum Relations"},{"key":"10.1016\/j.jfo.2016.12.004_bib0325","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bjo.2007.117812","article-title":"Prevalence of vernal keratoconjunctivitis: a rare disease?","volume":"92","author":"Bremond-Gignac","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0330","first-page":"S102","article-title":"Prevalence, burden, and pharmacoeconomics of dry eye disease","volume":"14","author":"Pflugfelder","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jfo.2016.12.004_bib0335","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.clae.2016.08.001","article-title":"Survey of eye practitioners\u2019 preference of diagnostic tests and treatment modalities for dry eye in Ghana","volume":"39","author":"Asiedu","year":"2016","journal-title":"Cont Lens Anterior Eye"},{"key":"10.1016\/j.jfo.2016.12.004_bib0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jcjo.2015.01.006","article-title":"Comparison of glaucoma knowledge and referral practices among family physicians with ophthalmologists\u2019 expectations","volume":"50","author":"Basilious","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0345","doi-asserted-by":"crossref","first-page":"64","DOI":"10.11622\/smedj.2016029","article-title":"Perioperative glycaemic control in diabetic patients undergoing cataract surgery under local anaesthesia: a survey of practices of Singapore ophthalmologists and anaesthesiologists","volume":"57","author":"Woo","year":"2016","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jfo.2016.12.004_bib0350","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/ICO.0000000000000123","article-title":"Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis","volume":"33","author":"Zhou","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2016.12.004_bib0355","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome","volume":"72","author":"Gunduz","year":"1994","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02697322","article-title":"Effect of topical cyclosporine on tear functions in tear-deficient dry eyes","volume":"39","author":"Jain","year":"2007","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0365","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.ophtha.2013.03.044","article-title":"Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis","volume":"120","author":"Wan","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2016.12.004_bib0370","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":"Vernal keratoconjunctivitis","volume":"18","author":"Bonini","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2016.12.004_bib0375","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1600-0420.1999.770217.x","article-title":"Toxicological evaluation of cyclosporine eyedrops","volume":"77","author":"Knagenhjelm","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jfo.2016.12.004_bib0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijpharm.2013.07.002","article-title":"Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation","volume":"455","author":"Luschmann","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jfo.2016.12.004_bib0385","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0181-5512(06)73780-9","article-title":"[Cytotoxicity evaluation of different eyes drops with cyclosporine oral solution (Sandimmun)]","volume":"29","author":"Nourry","year":"2006","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0390","first-page":"527","article-title":"[Cyclosporin A eyedrops: manufacturing, toxicity, pharmacokinetics and indications in 2000]","volume":"24","author":"Robert","year":"2001","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0395","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0181-5512(04)96181-5","article-title":"[Cyclosporine 2% eye drops preparation]","volume":"27","author":"Chast","year":"2004","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2016.12.004_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jop.1996.12.1","article-title":"Stability of cyclosporine 1% in artificial tears","volume":"12","author":"Fiscella","year":"1996","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551217300578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551217300578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:07:12Z","timestamp":1759259232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551217300578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0181551217300578"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2016.12.004","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-European survey of the topical ocular use of cyclosporine A","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}